Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3% below analysts’ consensus estimates.
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription drug prices.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
FDA approves Teva and Alvotech's Selarsdi as an interchangeable biosimilar to Stelara, supporting the treatment of multiple chronic inflammatory diseases.
REGENERON PHARMACEUTICALS has caught the attention as a great value stock. NASDAQ:REGN excels in profitability, solvency, and liquidity, all while being very reasonably priced.
Shares of Regeneron Pharmaceuticals are trading higher Wednesday recovering after a drop on Tuesday that followed the release of weaker-than-expected first quarter 2025 financial results.
